Skip to main content
SNSE
NASDAQ Life Sciences

Director Converts $619K Preferred Stock to Common After Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$13.85
Mkt Cap
$18.586M
52W Low
0
52W High
0
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Director Stephen M. Hahn converted $619,968 worth of preferred stock, obtained from the recent Faeth merger, into common stock, significantly increasing his direct common share ownership.


Key Events · Ownership and Investor Activity · SNSE

  • Director Converts Preferred Stock

    Director Stephen M. Hahn converted 44.763 shares of Series B Preferred Stock into 44,763 shares of common stock.

  • Significant Common Stock Holdings

    The acquired common stock is valued at $619,968, representing over 3% of the company's market capitalization.

  • Post-Merger Capital Restructuring

    This conversion follows the recent acquisition of Faeth Therapeutics and associated recapitalization efforts, aligning the director's equity more directly with common shareholders.

  • Option Grant Received

    The director also received a grant of 25,000 stock options, vesting over a three-year period.


Analysis · SNSE · Life Sciences

Director Stephen M. Hahn converted Series B Preferred Stock, which he received as part of the recent Faeth Therapeutics merger, into common stock. This conversion, valued at $619,968, significantly increases his direct common stock holdings by over 3% of the company's market capitalization. This action represents a material step in aligning his equity interests with common shareholders following the major recapitalization event and the integration of the acquired entity.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SNSE was trading at $13.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNSE - Latest Insights

SNSE
Jun 26, 2026, 7:40 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 24, 2026, 6:58 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 24, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 18, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 18, 2026, 4:01 PM EDT
Filing Type: S-3ASR
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info